Research Interests:
  • Cardiac computed tomography
  • Coronary flow reserve and alternatives to its measurement
  • Digital angiography
  • Endothelial dysfunction
  • Quantitative carotid ultrasound
  • Quantitative coronary angiography
  • Regression of atherosclerosis
  • Assessment of coronary interventional therapy (angioplasty, stents, atherectomy)
M.D. (with honours) University of Toronto
Recent Publications:
  • Johns K, Saeedi R, Mancini GBJ, Bondy G. Ankle Brachial Index Screening for Occult Vascular Disease is not Useful in HIV-positive Patients.  AIDS Research & Human Retroviruses 2010; 26(9):955-959.
  • LaBounty TM, Earls JP, Leipsic J, Heilbron B, Mancini GBJ, Lin FY, Dunning AM, Min JK.  Effect of Standardized Quality-Improvement Protocol on Radiation Dose in Coronary Computed Tomographic Angiography.  Am J Cardiol 2010;106:1663-1667.
  • LaBounty TM, Leipsic J, Mancini GBJ, Heilbron B, Patel S, Kazerooni EA, Sundaram B, Lin FY, Dunning A, Saltzan AJ, Weisz G, Weinsaft JW, Choi JH, Koduru S, Min JK. Effect of a Standardized Radiation Dose Reduction Protocol on Diagnostic Accuracy of Coronary Computed Tomographic Angiography.  Am J Cardiol. 2010 106(2):287-92.
  • Leipsic J, LaBounty TM, Heilbron B, Min JK, Mancini GBJ, Lin FY, Taylor C, Dunning A, Earls JP, Adaptive Statistical Iterative Reconstruction: Assessment of Image Noise and Image Quality in Coronary CT Angiography. AJR 2010; 195:649-654.
  • Leipsic J, LaBounty TM, Heilbron B, Min JK, Mancini GBJ, Lin FY, Taylor C, Dunning A, Earls JP, Estimated Radiation Dose Reduction Using Adaptive Statistical Iterative Reconstruction in Coronary CT Angiography: The ERASIR Study. AJR 2010; 195 655-660.
  • Maron DJ, Boden WE, O’Rourke RA, Hartigan PM, Calfas KJ, Mancini GBJ, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LJ, Berman DS, Chaitman BR, Weintraub WS, Teo KK, COURAGE Trial Research Group Intensive Multifactorial Intervention for Stable Coronary Artery Disease – Optimal Medical Therapy in the COURAGE Trial J Am Coll Cardiol 2010; 55:1348-58.
  • Steg G, Kerner A, Mancini GBJ, Reynolds HR, Carvalho A, Fridrich V, White HD, Forman SA, Lamas GA, Hochman JS, Buller CE Impact of Collateral Flow to the Occluded Infarct-Related Artery on Clinical Outcomes in Patients with Recent Myocardial Infarction: A Report from the Randomized Occluded Artery Trial Circulation 2010: 121:2724-2732.
  • Steigen TK, Buller CE, Mancini GBJ, Jorapur V, Cantor WJ, Rankin JM, Thomas B, Webb JG, Kronsberg SS, Atchison DJ, Lamas GA, Hochman JS, Dzavik V.  Myocardial Perfusion Grade after Late Infarct Artery Recanalization is Associated with Global and Regional Left Ventricular Function at One Year: Analysis from the Total Occlusion Study of Canada-2.  Circ Cardiovasc Interv. 2010;3:549-555.
  • Chaitman BR, Hartigan PM, Booth DC, Teo KK, Mancini GBJ, Kostuk WJ, Spertus JA, Maron DJ, Dada M, O’Rourke RA, Weintraub WS, Berman DS, Shaw LJ, Boden WE and on behalf of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Investigators. Do Major Cardiovascular Outcomes in Patients With Stable Ischemic Heart Disease in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial Differ by Healthcare System? Circ Cardiovasc Qual Outcomes published online Jul 27, 2010.
  • Benjamin JW Chow, Eric Larose, Sylvie Bilodeau, Mary Lou Ellins, Paul Galiwango, Malek Kass, Tej Sheth, Davinder S Jasal, Iain DC Kirkpatrick, GB John Mancini, John Mayo, Arun Abraham, James White, The ‘what, when, where, who, and how?’ of Cardiac Computed Tomography in 2009: Guidelines for the Clinician, Can J Cardiol 2009, 25(3): 135-139.
  • Boden WE, O’Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman, BR, Mancini, GBJ, Weintraub, WS on behalf of the COURAGE Trial Investigators, Impact of Optimal Medical Therapy With or Without Percutaneous Coronary Intervention on Long-Term Cardiovascular End Points in Patients with Stable Coronary Artery Disease (from the COURAGE Trial).  Am J Cardiol 2009;104:1-4.
  • Buller CE, Rankin JM, Carere RG, Buszman PE, Pfisterer ME, Dzavik V, Thomas B, Forman S, Ruzyllo W, Mancini GBJ, Michalis LK, Abreu PF, Lamas GA, Hochman JS. Percutaneous coronary intervention in the Occluded Artery Trial: Procedural success, hazard, and outcomes over 5 years; Am Heart J 2009; 158-408-15.
  • Dzavík V, Buller CE, Devlin G, Carere RG, Mancini GBJ, Cantor WJ, Buszman PE, Rankin JM, Vozzi C, Ross JR, Forman S, Barton BA, Lamas AG, Hochman JS. Angiographic and clinical outcomes of drug-eluting versus bare-metal stent deployment in the Occluded Artery Trial. Catheter Cardiovasc Interv 2009, May 1 73(6), 780.
  • Genest J. McPherson R. Frohlich J. Anderson T. Campbell N. Carpentier A. Couture P. Dufour R. Fodor G. Francis GA. Grover S. Gupta M. Hegele RA. Lau DC. Leiter L. Lewis GF. Lonn E. Mancini GB. Ng D. Pearson GJ. Sniderman A. Stone JA. Ur E.  2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations; Canadian Journal of Cardiology. October 2009; 25(10):567-79.
  • Hobbs FDR, Gensini G, Mancini GBJ, Manolis AJ, Bauer B, Genest J, Feldman RD, Harvey P, Jenssen TG, Marques da Silva P, for the JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehab 2009; 16(4); 472.
  • Kandzari DE, Rao SV, Moses JW, Dzavik V, Strauss BH, Kutryk MJ, Simonton CA, Garg J, Lokhnygina Y, Mancini GBJ, Yeoh E, Buller CE for the ACROSS/TOSCA-4 Investigators, Clinical and Angiographic Outcomes with Sirolimus-Eluting Stents in Total Coronary Occlusions: The ACROSS/TOSCA-4 (Approaches to Chronic Occlusions with Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) Trial, JACC Intervention 2009;2:97-106.
  • Malek LA, Reynolds H, Forman S, Vozzi C, Mancini GBJ, French J, Dziarmaga M, Renkin J, Kochman J, Lamas G, Hochman J. Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: Results fro the Occluded Artery Trial (OAT), Am Heart J 2009; 157:724-32.
  • Mancini GB John, Bates E, Maron D, Hartigan P, Dada M, Gosselin G, Kostuk W, Sedlis S, Shaw L, Berman D, Berger P, Spertus J, Mavromatis K, Knudtson M, Chaitman B, O’Rourke R, Weintraub W, Teo K, Boden W on behalf of the COURAGE Trial Investigators and Coordinators, Quantitative Results of Baseline Angiography and Percutaneous Coronary Intervention in the COURAGE Trial.  Circ Cardiovasc Qual Outcomes. 2009;2:320-327.
  • Maron DJ. Spertus JA. Mancini GB. Hartigan PM. Sedlis SP. Bates ER. Kostuk WJ. Dada M. Berman DS. Shaw LJ. Chaitman BR. Teo KK. O’Rourke RA. Weintraub WS. Boden WE. COURAGE Trial Research Group. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial; Am J Cardiol October 2009; 104(8):1055-62.
  • Mohamed A, Andrade J, Ignaszewski A, Mancini GBJ. Validity of carotid initima-media thickness as a surrogate endpoint for atherosclerosis: Lessons from the ENHANCE trial; BC Medical Journal 2009; 51; 168-172.
  • Scott A. Lear, Karin H. Humphries, Samantha Hage-Moussa, Arun Chockalingam, G.B. John Mancini, Immigration presents a potential increased risk for atherosclerosis. Atherosclerosis 205 (2009) 584–589.
  • Teo KK, Sedlis SP, Boden WE, O’Rourke RA, Maron DJ, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS, and the COURAGE Trial Investigators. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. J Am College of Cardiol Sep 2009; 54(14):13
  • Catalin Taraboanta, Evelyn Wu, Scott Lear, Stefanie DiPalma, John Hill, G.B. John Mancini, Jiri Frohlich, Subclinical atherosclerosis in subjects with family history of premature coronary artery disease. Am Heart J 2008,155:1020-1026.e1.
  • Erica Paras, G.B. John Mancini, Scott A. Lear.  The relationship of three common definitions of the metabolic syndrome with sub-clinical carotid atherosclerosis.  Atherosclerosis 2008; 198:228-236.
  • Jacqueline Saw, Cameron Demsem, Simon Walsh, Percy Jokhi, Andrew Starovoytov, Rebecca Fox, Graham Wong, Christopher Buller, Donald Ricci, G.B. John Mancini, Anthony Fung. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention. A BRIEF-PCI (Brief infusion of intraveneous eptifibatide following successful percutaneous coronary intervention) Trial Substudy.  JACC: Cardiovascular Interventions 2008; 1:654-9.
  • Leslee J Shaw, Daniel S Berman, David J Maron, G.B. John Mancini, Sean W Hayes, Pamela M Hartigan, William S Weintraub, Robert A O’Rourke, Marcin Dada, John A Spertus, Bernard R. Chaitman, John Friedman, Piotr Slomka, Gary V Heller, Guido Germano, Gilbert Gosselin, Peter Berger, William J Kostuk, Ronald G Schwartz, Merill Knudtson, Emir Veledar, Eric R Bates, Benjamin McCallister, Koon K Teo, William E Boden. Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Is
  • Mancini GBJ, Program Chair, Advances in Vascular Biology, Can J Cardiol, Aug 2008; 24 (supplement C).
  • Marco De Carlo, David A Wood, John G Webb, Ulrich Gerckens, Bernado Cortese, Eberhard Grube, G.B. John Mancini, Mitch W Krucoff, Colleen McQueen, Tom Goff, Anna S Petronio, Japp N Hamburger, Adjunctive use of the Rinspiration system for fluidic thrombectomy during primary angioplasty: the Rinspiration International Registry.  Catheterization and Cardiovascular Intervention 2008, 72:196-203.
  • Sammy Y Chan, G.B. John Mancini, Andrew Ignaszewski, Jiri Frohlich. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.  BMC Clinical Pharmacology 2008, 8:10 DOI: 10.1186/1472-6904-8-10.
  • Terje K Steigen, Cheryl Claudio, David Abbott, Michael Schulzer, Jeff Burton, Wayne Tymchak, Christopher E. Buller, G.B. John Mancini, Angiographic core laboratory reproducibility analyses: implications for planning clinical trials using coronary angiography and left ventriculography end-points.  Int J Cardiovasc Imaging 2008, 24:453-462.
  • Weintraub WS. Spertus JA. Kolm P. Maron DJ. Zhang Z. Jurkovitz C. Zhang W. Hartigan PM. Lewis C. Veledar E. Bowen J. Dunbar SB. Deaton C. Kaufman S. O’Rourke RA. Goeree R. Barnett PG. Teo KK. Boden WE. COURAGE Trial Research Group. Mancini GB.  Effect of PCI on quality of life in patients with stable coronary disease, New England Journal of Medicine. 359(7):677-87, 2008 Aug 14.
  • Jorapur V. Steigen TK. Buller CE. Dzavik V. Webb JG. Strauss BH. Yeoh EE. Kurray P. Sokalski L. Machado MC. Kronsberg SS. Lamas GA. Hochman JS. Mancini GB, Distribution and determinants of myocardial perfusion grade following late mechanical recanalization of occluded infarct-related arteries postmyocardial infarction: a report from the occluded artery trial. Catheterization & Cardiovascular Interventions. 72(6):783-9, 2008 Nov 15.
  • Scott A Lear, Karen H. Humphries, Simi Kohli, Jiri J. Frohlich, C. Laird Birmingham, G.B. John Mancini.  Visceral Adipose Tissue, a Potential Risk Factor for Carotid Atheroschlerosis: Results of the Multicultural Community Health Assessment Trial (M-CHAT) Stroke 2007;38;2422-2429; originally published online Aug 2, 2007; DOI: 10.1161/STROKEAHA.107.484113.
  • William E. Boden, Robert A. O’Rourke, Koon K. Teo, Pamela M. Hartigan, David J. Maron, William J. Kostuk, Merril Knudtson, Marcin Dada, Paul Casperson, Crystal L. Harris, Bernard R. Chaitman, Leslee Shaw, Gilbert Gosselin, Shah Nawaz, Lawrence M. Title, Gerald Gau, Alvin S. Blaustein, David C. Booth, Eric R. Bates, John A. Spertus, Daniel S. Berman, G.B. John Mancini, and William S. Weintraub, for the COURAGE Trial Research Group. Optimal Medical Therapy with or without PCI for Stable Coronary D
  • Mancini GBJ, Editor, Advances in Vascular Biology, Can J Cardiol, Feb 2006;22 (supplement B).
  • Webb J, Mann C, Hamburger J, Pate G, McManus B, Krucoff M, Mancini GBJ.  Initial Experience with a Novel Coronary Rinsing and Thrombectomy System: “Rinspiration”.  The Journal of Invasive Cardiology, May 2006;18:188-192.
  • “Chan SY, Mancini GBJ, Burns S, Johnson FF, Brozic AP, Kingsbury K, Barr S, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. Dietary Measures and Exercise Training Contribute to Improvement of Endothelial Function and Atherosclerosis Even in Patients Given Intensive Pharmacologic Therapy. Journal of Cardiopulmonary Rehabilitation 2006;26:288-293.
  • (Generated a simultaneous editorial: Kuvin, JT. Diet and Exercise: Are They Worth it in the Era of Advanced Pharmacotherapy? Journal of Cardiopulmona”
  • Dzavik V, Buller CE, Lamas GA, Rankin JM, Mancini GBJ, Cantor WJ, Carere RJ, Ross JR, Atchison D, Forman S, Thomas B, Buszman P, Vozzi C, Glanz A, Cohen EA, Meciar P, Devlin G, Mascette A, Sopko G, Knatterud GL, Hochman JS, for the TOSCA-2 Investigators. Randomized Trial of Percutaneous Coronary Intervention for Subacute Infarct-Related Coronary Artery Occlusion to Achieve Long-Term Patency and Improve Ventricular Function: The Total Occlusion Study of Canada (TOSCA-2) Trial. Circulation 2006; 1
  • Hobbs, F.D.R., Gensini G, Mancini GBJ, Manolis AJ, Bauer B, Böhler, Genest J, Feldman R, Harvey P, Jenssen TG, Metcalfe M, da Silva PM.  Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlopidine/atorvastatin) to atten recommended target levels for blood pressure and lipids (The Jewel Program).  Internationa
  • Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, Ruzyllo W, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, and Knatterud GL for the Occluded Artery Trial Investigators. Coronary Intervention for Persistent Occlusion after Myocardial Infarction. The New England Journal of Medicine. 2006; 355(23): 1-13.
  • Mancini, GBJ, Etiman M, Zhang, B, Levesque LE, Fitzgerald JM, Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers in patients with chronic obstructive pulmonary disease.  Journal of the American College of Cardiology, 2006; 47(12):2554-60.